Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: Results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial

HIV Medicine

Volumn 8, Issue 3, 2007, Pages 142-147

  Ghosn, Jade ^a   Quinson, A M ^b   Sabo, N D ^c   Cotte, L ^d   Piketty, C ^e   Dorleacq N ^b   Bravo, M L ^b   Mayers, D ^c   Harmenberg, J ^f   Mardh G ^f   Valdez, H ^c   Katlama, C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BOEHRINGER INGELHEIM   (France)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d HÔTEL DIEU   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f MEDIVIR AB   (Sweden)

Author keywords

Alovudine; HIV 1; Nucleoside reverse transcriptase inhibitor; Resistance; Thymidine analogue mutations; Viral load

Indexed keywords

3' FLUOROTHYMIDINE; ENFUVIRTIDE; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; THYMIDINE; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 34250359868     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00444.x     Document Type: Article

References (16)

1. Richman DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18: 1393-1401.
2. Johnson VA, Brun-Vézinet F, Clotet B et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11: 215-221.
3. Kantor R, Shafer RW, Follansbee S et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18: 1503-1511.
4. Mocroft A, Ledergerber B, Viard JP et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA Study Group. J Infect Dis 2004; 190: 1947-1956.
5. Camerman N, Mastropaolo D, Camerman A. Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus. Proc Natl Acad Sci USA 1990; 87: 3534-3537.
6. Flexner C, van der Horst C, Jacobson MA et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (Alovudine) and antiretroviral activity in two concentration controlled trials. J Infect Dis 1994; 170: 1394-1403.
7. Kim EY, Vrang L, Ǒberg B, Merigan TC. Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants. AIDS Res Human Retroviruses 2001; 17: 401-407.
8. Katlama C, Ghosn J, Tubiana R et al. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: Results from a 4-week phase II study. AIDS 2004; 18: 1299-1304.
9. Katlama C, Clotet B, Plettenberg A et al. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. HIV Med 2001; 2: 27-34.
10. Schooley RT, Ruane P, Myers RA et al. Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257-1263.
11. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16: 1227-1235.
12. FDA, Division of Antiviral Drug Products Advisory Committee. Tenofovir DF. 2001.
13. Molina JM, Marcelin AG, Pavie J et al. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: A randomized placebo-controlled trial. J Infect Dis 2005; 191: 840-847.
14. Connick E, Lederman MM, Kotzin B et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000; 181: 358-363.
15. Collier AC, Bozzette S, Coombs R et al. A pilot study of low dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990; 323: 1015-1021.
16. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. The Lancet 2000; 356: 1423-1430.